348,043 Shares in Elanco Animal Health Incorporated $ELAN Bought by Corient Private Wealth LP

Key Points

• Corient Private Wealth LP bought 348,043 Elanco Animal Health shares worth approximately $8.6 million, while institutional investors collectively own 97.48% of the company.
• Analyst sentiment remains generally positive, with a consensus “Moderate Buy” rating and a $29.09 target price; recent targets from JPMorgan and UBS rose to $30 and $33, respectively.
• Elanco beat quarterly expectations with $0.34 in EPS versus $0.27 expected and $1.37 billion in revenue, up 10.2% year over year. Company insiders also purchased 63,198 shares worth roughly $1.47 million over the past 90 days.

Corient Private Wealth LP purchased a new stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 348,043 shares of the company's stock, valued at approximately $8,565,000. Corient Private Wealth LP owned approximately 0.07% of Elanco Animal Health as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of ELAN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of Elanco Animal Health in the first quarter valued at $2,065,000. Goldman Sachs Group Inc. increased its stake in Elanco Animal Health by 104.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company's stock worth $50,268,000 after buying an additional 2,445,872 shares during the period. Empowered Funds LLC increased its stake in Elanco Animal Health by 35.2% during the 1st quarter. Empowered Funds LLC now owns 15,835 shares of the company's stock worth $166,000 after buying an additional 4,121 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Elanco Animal Health by 4.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,793,337 shares of the company's stock worth $18,830,000 after buying an additional 76,408 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its holdings in Elanco Animal Health by 2,006.9% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 310,383 shares of the company's stock worth $4,432,000 after buying an additional 295,651 shares in the last quarter. Institutional investors and hedge funds own 97.48% of the company's stock.

Analyst Ratings Changes

ELAN has been the subject of several recent analyst reports. Piper Sandler restated an "overweight" rating on shares of Elanco Animal Health in a research note on Monday, June 29th. Wall Street Zen cut Elanco Animal Health from a "strong-buy" rating to a "buy" rating in a research note on Sunday, May 24th. JPMorgan Chase & Co. boosted their price target on Elanco Animal Health from $28.00 to $30.00 and gave the stock an "overweight" rating in a research note on Thursday, May 7th. Weiss Ratings downgraded Elanco Animal Health from a "sell (d+)" rating to a "sell (d)" rating in a report on Thursday, August 20th. Finally, UBS Group raised their price objective on Elanco Animal Health from $31.00 to $33.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $29.09.

Elanco Animal Health Stock Performance

Shares of ELAN stock opened at $24.16 on Monday. Elanco Animal Health Incorporated has a 12-month low of $17.11 and a 12-month high of $27.98. The firm has a market capitalization of $12.07 billion, a price-to-earnings ratio of -58.93, a price-to-earnings-growth ratio of 1.44 and a beta of 1.67. The business has a 50 day simple moving average of $24.62 and a 200 day simple moving average of $24.00. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.05 and a quick ratio of 1.10.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 EPS for the quarter, beating analysts' consensus estimates of $0.27 by $0.07. The business had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.31 billion. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The business's revenue for the quarter was up 10.2% on a year-over-year basis. During the same quarter last year, the business earned $0.26 earnings per share. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. On average, equities research analysts anticipate that Elanco Animal Health Incorporated will post 1.12 EPS for the current year.

Insider Activity

In related news, Director Lawrence Erik Kurzius purchased 40,000 shares of the company's stock in a transaction on Thursday, August 20th. The shares were bought at an average price of $23.40 per share, with a total value of $936,000.00. Following the completion of the acquisition, the director owned 188,647 shares of the company's stock, valued at approximately $4,414,339.80. This represents a 26.91% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Robert M. Vanhimbergen acquired 4,200 shares of the business's stock in a transaction dated Friday, August 7th. The shares were bought at an average price of $23.08 per share, with a total value of $96,936.00. Following the transaction, the chief financial officer directly owned 137,516 shares in the company, valued at approximately $3,173,869.28. The trade was a 3.15% increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased a total of 63,198 shares of company stock valued at $1,473,109 in the last ninety days. 1.14% of the stock is owned by company insiders.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco's portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source